Moderna reports first positive Phase 3 for mRNA neoantigen therapy in melanoma
Moderna and Merck report their personalized mRNA-based melanoma vaccine has met key endpoints in a Phase 3 trial, prompting optimism that this could be a major advance in cancer immunotherapy and broader validation of mRNA as a therapeutic platform. Commenters weigh the potential health impact against concerns over the lack of published data so far, market overreaction to a press release, and likely high costs, while also reflecting on existing melanoma treatments, prevention, and the mixed track record of past cancer trials.
Clinical trial result and significance
- Phase 3 melanoma trial of a personalized mRNA neoantigen vaccine plus Keytruda reportedly met endpoints for recurrence‑free and distant metastasis‑free survival.
- Some see this as a “huge win,” especially since it’s compared against an already effective standard (Keytruda alone), not placebo.
- Others are cautious: no detailed Phase 3 data (hazard ratios, survival curves, CIs) are public yet; prior Phase 2 data had design quirks and borderline stats.
Stock market reaction and valuation
- Moderna’s stock jumped ~150%.
- Supporters argue this reflects:
- The potential revenue from a successful front‑line melanoma therapy.
- Platform validation for personalized mRNA, increasing the value of the broader pipeline.
- Skeptics call the move overextended or “insane,” noting it’s based on press releases without full data, and warning of historic overpricing in biotech.
mRNA cancer vaccines and immunotherapy
- Many commenters are excited that mRNA is proving useful beyond COVID, with other examples like flu vaccines.
- Personalized mRNA cancer vaccines are seen as a logical but newly practical extension of decades of immunotherapy work.
- Discussion notes challenges: picking the right neoantigens, limited data, and crude current heuristics; machine learning is used but not clearly deep learning.
- Some argue immunotherapy has been transformative in several cancers; others say gains are often modest in survival months and “revolutionized” is overstated.
Melanoma, sun exposure, and prevention
- Long thread on sun risk: UV index vs temperature, clouds and snow still allowing/boosting UV, geography and altitude effects.
- Debate over how strongly melanoma vs other skin cancers are linked to UV; one cited estimate attributes ~80% of cutaneous melanoma to UV, but relative strength vs other cancers is disputed.
- Historical attitudes toward sun (bonnets, class fashion, “heliotherapy”) are discussed; people note both folk awareness of burns and widespread past ignorance of cancer risk.
Safety, side effects, and risk trade‑offs
- Some express high tolerance for side effects in late‑stage cancer, arguing even risky therapies can be worthwhile.
- Others recount harsh chemotherapy experiences and question net benefit in specific cases.
- A subset is wary of mRNA generally, raising concerns about dose control, long‑lasting protein expression, myocarditis, and comparisons to past drug safety failures; others counter that cancer risk profiles differ and that COVID itself carried higher myocarditis risk.
Cost, access, and policy
- Concerns raised that personalized therapies will be extremely expensive and burden taxpayers, with unclear impact on overall life expectancy.
- Others defend “big pharma” for taking on risky R&D.
- A linked commentary criticizes recent cuts to public mRNA research funding and claims about the platform being “no longer viable.”
Human impact
- Several commenters share painful stories of relatives dying from melanoma or other cancers and express regret these options weren’t available earlier, underscoring the stakes behind the technical and financial debates.